n-methyl-3,4-methylenedioxyamphetamine has been researched along with Parkinson Disease in 12 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Drugs used for the treatment of Parkinson's disease and endocrine diseases, like hyperprolactinemia, may also induce VHD." | 2.49 | Drug-induced valvular heart disease. ( Cosyns, B; Droogmans, S; Lancellotti, P; Rosenhek, R, 2013) |
| "He had a family history of Parkinson's disease, though the onset of his symptoms was significantly earlier than those of his family members." | 1.91 | Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report. ( Guo, S; Hui, T, 2023) |
| " These data identify a new class of therapeutic in Parkinson's disease and highlight the potential benefits of studying illicit drugs that in themselves would never be considered safe for long-term therapy." | 1.38 | A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. ( Brotchie, JM; Fox, SH; Gandy, MN; Gomez-Ramirez, J; Huot, P; Johnston, TH; Lee, J; Lewis, KD; Martin-Iverson, M; McIldowie, M; Millar, Z; Nash, JE; Piggott, MJ; Salomonczyk, D; Thiele, S; Wagg, K; Yong-Kee, CJ, 2012) |
| " In a forward genetic screen, we identified a mutant resistant to the toxic effects of dopamine." | 1.37 | A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity. ( McIntire, SL; Schreiber, MA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, X | 1 |
| Li, S | 1 |
| Li, J | 1 |
| Qi, R | 1 |
| Zhong, L | 1 |
| Yu, H | 1 |
| Hui, T | 1 |
| Guo, S | 1 |
| Sgambato, V | 1 |
| Nichols, D | 1 |
| Schreiber, MA | 1 |
| McIntire, SL | 1 |
| Johnston, TH | 1 |
| Millar, Z | 1 |
| Huot, P | 1 |
| Wagg, K | 1 |
| Thiele, S | 1 |
| Salomonczyk, D | 1 |
| Yong-Kee, CJ | 1 |
| Gandy, MN | 1 |
| McIldowie, M | 1 |
| Lewis, KD | 1 |
| Gomez-Ramirez, J | 1 |
| Lee, J | 1 |
| Fox, SH | 1 |
| Martin-Iverson, M | 1 |
| Nash, JE | 1 |
| Piggott, MJ | 1 |
| Brotchie, JM | 1 |
| Cosyns, B | 1 |
| Droogmans, S | 1 |
| Rosenhek, R | 1 |
| Lancellotti, P | 1 |
| Lebsanft, HB | 1 |
| Mayerhofer, A | 1 |
| Kovar, KA | 1 |
| Schmidt, WJ | 1 |
| Holden, C | 1 |
| O'Suilleabhain, P | 1 |
| Giller, C | 1 |
| Morton, J | 1 |
| Cadet, JL | 1 |
| Brannock, C | 1 |
3 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Parkinson Disease
| Article | Year |
|---|---|
Drug-induced valvular heart disease.
Topics: Dopamine Agonists; Ergolines; Global Health; Heart Valve Diseases; Humans; N-Methyl-3,4-methylenedio | 2013 |
Ecstasy: pharmacology and neurotoxicity.
Topics: Affect; Animals; Binding Sites; Brain; Fever; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamph | 2005 |
Free radicals and the pathobiology of brain dopamine systems.
Topics: Animals; Brain; Dopamine; Free Radicals; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyampheta | 1998 |
9 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Parkinson Disease
| Article | Year |
|---|---|
MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson's disease progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; Dopaminergic Neurons; Humans; MicroRNAs; | 2023 |
Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.
Topics: Adult; Dopamine; Humans; Male; Methamphetamine; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; | 2023 |
Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
Topics: Animals; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Haplorhini; Humans; Levodopa; N | 2021 |
Legal highs: the dark side of medicinal chemistry.
Topics: Amphetamines; Animals; Depression; Designer Drugs; Drug Design; Electronic Mail; Hallucinogens; Huma | 2011 |
A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dopamine; Dopamine Agents; Immunit | 2011 |
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
Topics: Animals; Antiparkinson Agents; Benzodioxoles; Cell Line, Tumor; Drug Synergism; Levodopa; Male; Meth | 2012 |
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Citalopram | 2003 |
Retraction. Paper on toxic party drug is pulled over vial mix-up.
Topics: Animals; Dopamine; Drug Labeling; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; N | 2003 |
Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.
Topics: Adult; Antiparkinson Agents; Disease Progression; Hallucinogens; Hepatitis C; Humans; Indoles; Male; | 2003 |